Skip to main content

Table 5 Radiological and Laboratory Results and Treatment Prescription at Triage and during the follow-up in 110 Presumed Drug Resistant Tuberculosis Cases

From: Outcomes from patients with presumed drug resistant tuberculosis in five reference centers in Brazil

Variable DS-TB DR/MDR-TB   MDR-TB p value
N (%) N (%) OR(95% CI) p value N (%) OR(95% CI)  
Treatment and Laboratory results at Triage
 AFB at triagem        
  Pos 53(89.8) 41(80.4) 1.0 (Reference) p = 0.34 24(77.4) 1.0 (Reference) p = 0.19
  Neg 6(10.2) 8(15.7) 0.58(0.18–1.80)   6(19.3) 0.45 (0.13–1.55)  
  IGN 0 2(3.9)    1(3.2)   
 HIV testing result
  Positive 9(15.3) 3(5.9) 1.0 (Reference) p = 0.06 3(9.7) 1.0 (Reference) p = 0.33
  Negative 27(45.8) 34(62.7) 0.26(0.06–1.07)   18(56.1) 0.50 (0.11–2.10)  
  IGN 11(38.9) 14(27.4) -   10(32.2)   
 Chest X Ray(Images)
  Typical 56(94.8) 45(88.2) 1.0 (Reference) p = 0.08 25(80.6) 1.0 (Reference) p = 0.01
  Compatible 1(1.9) 6(11.8) 0.13(0.01–1.15)   6(19.4) 0.07(0.008–0.65)  
  Atipical 2(3.3) 0 -   0   
 Cavitation
  Yes 52(88.1) 40(78.4) 1.0 (Reference) p = 0.16 23(74.2) 1.0 (Reference) p = 0.19
  No 6(10.0) 10(19.5) 0.46(0.15–1.37)   7(22.6) 0.37 (0.11–1.25)  
  IGN 1(1.9) 1(1.9)    1(3.2)   
 Empirical treament
  Yes 58 (98.3) 48(94.1) 1.0 (Reference) p = 0.51 28(90.3) 1.0 (Reference) p = 0.23
  1st line drugs 51 34 0.27(0.02–2.73)   12 0.16(0.01–1.61)  
  2nd line drugs 7 14    16   
  No 1 (1.7) 3 (5.9)    3(9.7)   
 Anti_TB drugs prescribed at triage
  Maintained the regimen 18(30.5) 18(35.3) 1.0(Reference) p = 0.59 12(38.7) 1.0 (Reference) p = 0.43
  Start new TB regimen 41(69.5) 33(64.7) 1.24(0.56–2.76)   19(61.3) 1.44(0.57–3.57)  
Treatment and Laboratory results among 95 pDR-TB Followed-up
 Adverse reaction
  Yes 7(15.6) 11(22.0) 1.0 (Reference) p = 0.88 8(27.6) 1.0 (Reference) p = 0.82
  No 20(44.5) 34(68.0) 0.92(0.30–2.76)   20(68.9) 1.14(0.34–3.75)  
  IGN 18(40.0) 5(10.0)    1(3.4)   
 Change of treat
  Yes 9(20.0) 27(54.0) 1.0 (Reference) p = 0.03 20(68.9) 1.0 (Reference) p < 0.01
  Use DST results 3 21 2.85(1.06–7.60)   16 4.69(1.53–14.34)  
  Other 6 6    4   
  No 19(42.0) 20(40.0)    9(31.1)   
  IGN 17(37.8) 3(6.0)      
 AFB 6th month
  Positive 2(4.5) 6(12.0) 1.0 (Reference) p = 0.35 4(13.8) 1.0 (Reference) p = 0.49
  Negative 17(37.8) 23(46.0) 2.21(0.39–12.36)   12(41.4) 2.80(0.44–18.0)  
  IGN 26(57.8) 21 (42.0)    13 (44.8)   
 Culture results 6th month
  Pos 1(2.2) 10(20.0) 1.0 (Reference) p = 0.10 6(20.7) 1.0 (Reference) p = 0.17
  Neg 12(26.7) 17(34.0) 7.05(0.79–62.72)   11(37.9) 6.54(0.67–63.33)  
  Cont 1(2.2) 1(2.0) -   0   
  IGN 31(68.9) 22(44.0)    12 (41.4)   
 Treatment Outcome at 6th month
  Favourable 23(51.0) 33(66.0) 2.42(1.02–5.78) p = 0.04 21(72.4) 2.51(0.92–6.84) p = 0.07
  Unfavourable 22(48.9) 13(26.0) 1.0 (Reference)   8(27.6) 1.0 (Reference)  
  Default 20 2    1   
  Failure 1 10    6   
  Death 1 1    1   
  Transfer - 4(8.0)      
  1. IGN ignored, NA not applicable, MDR multidrug resistant, DR drug resistant; DS drug sensitive